A Randomized, Control, Parallel, Open Label, Multi-centre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy

NCT01252056 Phase 4 COMPLETED

The efficacy and safety of Cilostazol and Probucol in combination on patients with diabetic nephropathy is better than the single use.

Details

Lead sponsor	Otsuka Beijing Research Institute
Phase	Phase 4
Status	COMPLETED
Enrolment	353
Start date	2010-03
Completion	2012-12

Conditions

• Diabetic Nephropathy

Interventions

• Probucol
• Probucol and Cilostazol

Primary outcomes

• nephropathy development — 96W
  After 96-week treatment, compare the efficacy between Probucol group and group control group on deferring nephropathy development of the patients with diabetic nephropathy (including: the change value of urine albumin from the baseline, the rate of the patients with serum creatinine reaching a doubling of the base-line serum creatinine, the rate of the hemodialysis-free survival)

Countries

China